{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:30:55Z","timestamp":1789525855346,"version":"build-2803163510"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Antigen-specific immunotherapies, in particular peptide vaccines, depend on the recognition of naturally presented antigens derived from mutated and unmutated gene products on human leukocyte antigens, and represent a promising low-side-effect concept for cancer treatment. So far, the broad application of peptide vaccines in cancer patients is hampered by challenges of time- and cost-intensive personalized vaccine design, and the lack of neoepitopes from tumor-specific mutations, especially in low-mutational burden malignancies. In this study, we developed an immunopeptidome-guided workflow for the design of tumor-associated off-the-shelf peptide warehouses for broadly applicable personalized therapeutics. Comparative mass spectrometry-based immunopeptidome analyses of primary chronic lymphocytic leukemia (CLL) samples, as representative example of low-mutational burden tumor entities, and a dataset of benign tissue samples enabled the identification of high-frequent non-mutated CLL-associated antigens. These antigens were further shown to be recognized by pre-existing and<jats:italic>de novo<\/jats:italic>induced T cells in CLL patients and healthy volunteers, and were evaluated as pre-manufactured warehouse for the construction of personalized multi-peptide vaccines in a first clinical trial for CLL (NCT04688385). This workflow for the design of peptide warehouses is easily transferable to other tumor entities and can provide the foundation for the development of broad personalized T\u00a0cell-based immunotherapy approaches.<\/jats:p>","DOI":"10.3389\/fimmu.2021.705974","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T09:27:52Z","timestamp":1625736472000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia"],"prefix":"10.3389","volume":"12","author":[{"given":"Annika","family":"Nelde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacine","family":"Maringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Bilich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut R.","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Roerden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas S.","family":"Heitmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Marcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian C.","family":"Neidert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Denzlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Illerhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Erich","family":"Aulitzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Georg","family":"Rammensee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane S.","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991","article-title":"An Immunogenic Personal Neoantigen Vaccine for Patients With Melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14001","article-title":"Predicting Immunogenic Tumour Mutations by Combining Mass Spectrometry and Exome Sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"a028829","DOI":"10.1101\/cshperspect.a028829","article-title":"Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens: Nothing New in Spite of the Name","volume":"10","author":"Finn","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-099366","article-title":"RHAMM-R3 Peptide Vaccination in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Multiple Myeloma Elicits Immunologic and Clinical Responses","volume":"111","author":"Schmitt","year":"2008","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively Personalized Vaccination Trial for Newly Diagnosed Glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405884101","article-title":"Induction of WT1 (Wilms' Tumor Gene)-Specific Cytotoxic T Lymphocytes by WT1 Peptide Vaccine and the Resultant Cancer Regression","volume":"101","author":"Oka","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2883","article-title":"Multipeptide Immune Response to Cancer Vaccine IMA901 After Single-Dose Cyclophosphamide Associates With Longer Patient Survival","volume":"18","author":"Walter","year":"2012","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1385","article-title":"Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated After Chemoradiotherapy and an 8-Year Update on a Phase I\/II Trial","volume":"17","author":"Brunsvig","year":"2011","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.4048","article-title":"Evaluation of Safety, Immunogenicity, and Preliminary Efficacy of PolyPEPI1018 Off-the-Shelf Vaccine With Fluoropyrimidine\/Bevacizumab Maintenance Therapy in Metastatic Colorectal Cancer (mCRC) Patients","volume":"38","author":"Hubbard","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.eururo.2015.12.050","article-title":"A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy With Low-Dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-Naive Castration-Resistant Prostate Cancer","volume":"70","author":"Yoshimura","year":"2016","journal-title":"Eur Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29909","article-title":"Immune Responses to WT1 in Patients With AML or MDS After Chemotherapy and Allogeneic Stem Cell Transplantation","volume":"138","author":"Casalegno-Garduno","year":"2016","journal-title":"Int J Cancer J Int du Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0142310","DOI":"10.1371\/journal.pone.0142310","article-title":"Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients With Chronic Lymphocytic Leukemia","volume":"10","author":"Hojjat-Farsangi","year":"2015","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1416389112","article-title":"HLA Ligandome Analysis Identifies the Underlying Specificities of Spontaneous Antileukemia Immune Responses in Chronic Lymphocytic Leukemia (CLL)","volume":"112","author":"Kowalewski","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3185","article-title":"Analysis of Spontaneous Tumor-Specific CD4 T-Cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect With Chemotherapy Response","volume":"18","author":"Godet","year":"2012","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"100022","DOI":"10.1074\/mcp.R120.002309","article-title":"The Peptide Vaccine of the Future","volume":"20","author":"Nelde","year":"2021","journal-title":"Mol Cell Proteomics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"13404","DOI":"10.1038\/ncomms13404","article-title":"Direct Identification of Clinically Relevant Neoepitopes Presented on Native Human Melanoma Tissue by Mass Spectrometry","volume":"7","author":"Bassani-Sternberg","year":"2016","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M600310-MCP200","article-title":"Distorted Relation Between mRNA Copy Number and Corresponding Major Histocompatibility Complex Ligand Density on the Cell Surface","volume":"6","author":"Weinzierl","year":"2007","journal-title":"Mol Cell Proteomics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1084\/jem.20071985","article-title":"The MHC Class I Peptide Repertoire is Molded by the Transcriptome","volume":"205","author":"Fortier","year":"2008","journal-title":"J Exp Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M114.042812","article-title":"Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation","volume":"14","author":"Bassani-Sternberg","year":"2015","journal-title":"Mol Cell Proteomics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1836-9","article-title":"The Natural HLA Ligandome of Glioblastoma Stem-Like Cells: Antigen Discovery for T Cell-Based Immunotherapy","volume":"135","author":"Neidert","year":"2018","journal-title":"Acta Neuropathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-866830","article-title":"The HLA Ligandome Landscape of Chronic Myeloid Leukemia Delineates Novel T-Cell Epitopes for Immunotherapy","volume":"133","author":"Bilich","year":"2019","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.233","article-title":"Mapping the HLA Ligandome Landscape of Acute Myeloid Leukemia: A Targeted Approach Toward Peptide-Based Immunotherapy","volume":"29","author":"Berlin","year":"2015","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-640532","article-title":"The Antigenic Landscape of Multiple Myeloma: Mass Spectrometry (Re)Defines Targets for T-Cell-Based Immunotherapy","volume":"126","author":"Walz","year":"2015","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1707658114","article-title":"The Immunopeptidomic Landscape of Ovarian Carcinomas","volume":"114","author":"Schuster","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13073-020-00731-8","article-title":"Integrative -Omics and HLA-Ligandomics Analysis to Identify Novel Drug Targets for ccRCC Immunotherapy","volume":"12","author":"Reustle","year":"2020","journal-title":"Genome Med"},{"key":"B26","article-title":"\"Spontaneous\" Complete Remissions in Chronic Lymphocytic Leukemia: Report of Three Cases and Review of the Literature","volume":"12","author":"Ribera","year":"1987","journal-title":"Blood Cells"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and Allogeneic Stem Cell Transplantations for Poor-Risk Chronic Lymphocytic Leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9450-2_10","article-title":"Purification and Identification of Naturally Presented MHC Class I and II Ligands","volume":"1988","author":"Nelde","year":"2019","journal-title":"Methods Mol Biol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1182\/blood.V128.22.3234.3234","article-title":"HLA Ligandome Analysis of Primary Chronic Lymphocytic Leukemia (CLL) Cells Under Lenalidomide Treatment Confirms the Suitability of Lenalidomide for Combination With T-Cell-Based Immunotherapy","volume":"128","author":"Nelde","year":"2018","journal-title":"Oncoimmunology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/1044-0305(94)80016-2","article-title":"An Approach to Correlate Tandem Mass Spectral Data of Peptides With Amino Acid Sequences in a Protein Database","volume":"5","author":"Eng","year":"1994","journal-title":"J\u00a0Am Soc Mass Spectrom"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0255-1","article-title":"CLL Cells Cumulate Genetic Aberrations Prior to the First Therapy Even in Outwardly Inactive Disease Phase","volume":"33","author":"Hernandez-Sanchez","year":"2019","journal-title":"Leukemia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.02.002","article-title":"Gene Mutations in Chronic Lymphocytic Leukemia","volume":"43","author":"Amin","year":"2016","journal-title":"Semin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: The Catalogue Of Somatic Mutations In Cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth1113","article-title":"Semi-Supervised Learning for Peptide Identification From Shotgun Proteomics Datasets","volume":"4","author":"Kall","year":"2007","journal-title":"Nat Methods"},{"key":"B35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-1-60327-118-9_5","article-title":"SYFPEITHI: Database for Searching and T-Cell Epitope Prediction","volume":"409","author":"Schuler","year":"2007","journal-title":"Methods Mol Biol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00251-008-0341-z","article-title":"NetMHCpan, a Method for MHC Class I Binding Prediction Beyond Humans","volume":"61","author":"Hoof","year":"2009","journal-title":"Immunogenetics"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1038\/ncomms2610","article-title":"Mouse Urinary Peptides Provide a Molecular Basis for Genotype Discrimination by Nasal Sensory Neurons","volume":"4","author":"Sturm","year":"2013","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.O113.036475","article-title":"Conserved Peptide Fragmentation as a Benchmarking Tool for Mass Spectrometers and a Discriminating Feature for Targeted Proteomics","volume":"13","author":"Toprak","year":"2014","journal-title":"Mol Cell Proteomics"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26365","article-title":"Promiscuous Survivin Peptide Induces Robust CD4+ T-Cell Responses in the Majority of Vaccinated Cancer Patients","volume":"131","author":"Widenmeyer","year":"2012","journal-title":"Int J Cancer J Int du Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5284.94","article-title":"Phenotypic Analysis of Antigen-Specific T Lymphocytes","volume":"274","author":"Altman","year":"1996","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e1065369","DOI":"10.1080\/2162402X.2015.1065369","article-title":"HLA Ligandomics Identifies Histone Deacetylase 1 as Target for Ovarian Cancer Immunotherapy","volume":"5","author":"Peper","year":"2016","journal-title":"Oncoimmunology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1454-2","article-title":"Identification of HLA Ligands and T-Cell Epitopes for Immunotherapy of Lung Cancer","volume":"62","author":"Neumann","year":"2013","journal-title":"Cancer Immunol Immunother CII"},{"key":"B44","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1186\/1471-2164-9-488","article-title":"BioVenn - A Web Application for the Comparison and Visualization of Biological Lists Using Area-Proportional Venn Diagrams","volume":"9","author":"Hulsen","year":"2008","journal-title":"BMC Genomics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2105-7-153","article-title":"Predicting Population Coverage of T-Cell Epitope-Based Diagnostics and Vaccines","volume":"7","author":"Bui","year":"2006","journal-title":"BMC Bioinform"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku938","article-title":"The Immune Epitope Database (IEDB) 3.0","volume":"43","author":"Vita","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-Term Efficacy and Safety of First-Line Ibrutinib Treatment for Patients With CLL\/SLL: 5 Years of Follow-Up From the Phase 3 RESONATE-2 Study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"New Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens Versus Chemoimmunotherapy in Older Patients With Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e1700465","DOI":"10.1002\/pmic.201700465","article-title":"Immunopeptidomic Profiling of HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens","volume":"18","author":"Ternette","year":"2018","journal-title":"Proteomics"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2881","article-title":"A Pan-Cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients With Various Types of Advanced Solid Tumors","volume":"26","author":"Fang","year":"2020","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy200","article-title":"A Randomized, Double-Blind, Phase III Trial of Personalized Peptide Vaccination for Recurrent Glioblastoma","volume":"21","author":"Narita","year":"2019","journal-title":"Neuro Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nature23003","article-title":"Personalized RNA Mutanome Vaccines Mobilize Poly-Specific Therapeutic Immunity Against Cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12936","article-title":"Mapping the Tumour Human Leukocyte Antigen (HLA) Ligandome by Mass Spectrometry","volume":"154","author":"Freudenmann","year":"2018","journal-title":"Immunology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma","volume":"31","author":"van Rooij","year":"2013","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1172\/JCI88590","article-title":"MHC Class I-Associated Peptides Derive From Selective Regions of the Human Genome","volume":"126","author":"Pearson","year":"2016","journal-title":"J Clin Invest"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01981","article-title":"Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference","volume":"11","author":"Marino","year":"2020","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403186","article-title":"Complete Remission in a Patient With Recurrent Acute Myeloid Leukemia Induced by Vaccination With WT1 Peptide in the Absence of Hematological or Renal Toxicity","volume":"18","author":"Mailander","year":"2004","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1008051107","article-title":"Induction of Complete and Molecular Remissions in Acute Myeloid Leukemia by Wilms' Tumor 1 Antigen-Targeted Dendritic Cell Vaccination","volume":"107","author":"Van Tendeloo","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"eabd8636","DOI":"10.1126\/scitranslmed.abd8636","article-title":"Epitope Spreading Toward Wild-Type Melanocyte-Lineage Antigens Rescues Suboptimal Immune Checkpoint Blockade Responses","volume":"13","author":"Lo","year":"2021","journal-title":"Sci Transl Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02370-4","article-title":"Immunity to X-Linked Inhibitor of Apoptosis Protein (XIAP) in Malignant Melanoma and Check-Point Blockade","volume":"68","author":"Zhou","year":"2019","journal-title":"Cancer Immunol Immunother CII"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5BT0119-016R","article-title":"At the Bench: Engineering the Next Generation of Cancer Vaccines","volume":"108","author":"Shae","year":"2020","journal-title":"J Leukoc Biol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000252","article-title":"Identification of Immunogenic Epitopes by MS\/MS","volume":"23","author":"Di Marco","year":"2017","journal-title":"Cancer J"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/351290a0","article-title":"Allele-Specific Motifs Revealed by Sequencing of Self-Peptides Eluted From MHC Molecules","volume":"351","author":"Falk","year":"1991","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1038\/bcj.2016.14","article-title":"Carfilzomib Alters the HLA-Presented Peptidome of Myeloma Cells and Impairs Presentation of Peptides With Aromatic C-Termini","volume":"6","author":"Kowalewski","year":"2016","journal-title":"Blood Cancer J"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.167312","article-title":"Mass Spectrometry-Based Identification of a Naturally Presented Receptor Tyrosine Kinase-Like Orphan Receptor 1-Derived Epitope Recognized by CD8(+) Cytotoxic T Cells","volume":"102","author":"Heidenreich","year":"2017","journal-title":"Haematologica"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nature01441","article-title":"CD4+ T Cells are Required for Secondary Expansion and Memory in CD8+ T Lymphocytes","volume":"421","author":"Janssen","year":"2003","journal-title":"Nature"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0183-1","article-title":"Immune Selective Pressure and HLA Class I Antigen Defects in Malignant Lesions","volume":"56","author":"Chang","year":"2007","journal-title":"Cancer Immunol Immunother CII"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200405000-00002","article-title":"Identification of Multiple Antigens Recognized by Tumor-Infiltrating Lymphocytes From a Single Patient: Tumor Escape by Antigen Loss and Loss of MHC Expression","volume":"27","author":"Khong","year":"2004","journal-title":"J Immunother"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00017","article-title":"T Cell Dysfunction and Exhaustion in Cancer","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1006500107","article-title":"Success or Failure of Vaccination for HPV16-Positive Vulvar Lesions Correlates With Kinetics and Phenotype of Induced T-Cell Responses","volume":"107","author":"Welters","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2737","article-title":"Amplification of Tumor-Specific Regulatory T Cells Following Therapeutic Cancer Vaccines","volume":"107","author":"Zhou","year":"2006","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0337-2","article-title":"The Future of Cancer Immunotherapy: Microenvironment-Targeting Combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41419-017-0061-0","article-title":"Defining the Role of the Tumor Vasculature in Antitumor Immunity and Immunotherapy","volume":"9","author":"Schaaf","year":"2018","journal-title":"Cell Death Dis"},{"key":"B76","doi-asserted-by":"publisher","first-page":"134ra62","DOI":"10.1126\/scitranslmed.3003330","article-title":"CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert With Immunotherapy in Cancer Patients","volume":"4","author":"Rech","year":"2012","journal-title":"Sci Transl Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41467-020-14471-1","article-title":"Bempegaldesleukin Selectively Depletes Intratumoral Tregs and Potentiates T Cell-Mediated Cancer Therapy","volume":"11","author":"Sharma","year":"2020","journal-title":"Nat Commun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0301","article-title":"Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T Cells in Cancer Immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S265828","article-title":"Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions","volume":"12","author":"Zeng","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B81","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.204.Supp.239.34","article-title":"Heteroclitic Peptide Cancer Vaccine Counters MHC-I Skewing in Mutant Calreticulin-Positive Myeloproliferative Neoplasms","volume":"204","author":"Gigoux","year":"2020","journal-title":"J Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e1252895","DOI":"10.1080\/2162402X.2016.1252895","article-title":"An Immunogenic WT1-Derived Peptide That Induces T Cell Response in the Context of HLA-A* 02: 01 and HLA-A* 24: 02 Molecules","volume":"6","author":"Dao","year":"2017","journal-title":"Oncoimmunology"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer Immunotherapy Using Checkpoint Blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B84","doi-asserted-by":"publisher","first-page":"792","DOI":"10.4049\/jimmunol.1701644","article-title":"PD-1 Blockade Unleashes Effector Potential of Both High-and Low-Affinity Tumor-Infiltrating T Cells","volume":"201","author":"Mart\u00ednez-Usatorre","year":"2018","journal-title":"J Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1758835919830826","DOI":"10.1177\/1758835919830826","article-title":"Combined Targeted Therapy and Immunotherapy in Melanoma: A Review of the Impact on the Tumor Microenvironment and Outcomes of Early Clinical Trials","volume":"11","author":"Pelster","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30408-9","article-title":"IMA901, a Multipeptide Cancer Vaccine, Plus Sunitinib Versus Sunitinib Alone, as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma (IMPRINT): A Multicentre, Open-Label, Randomised, Controlled, Phase 3 Trial","volume":"17","author":"Rini","year":"2016","journal-title":"Lancet Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clim.2009.11.013","article-title":"Sunitinib Impairs the Proliferation and Function of Human Peripheral T Cell and Prevents T-Cell-Mediated Immune Response in Mice","volume":"135","author":"Gu","year":"2010","journal-title":"Clin Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients With Chronic Lymphocytic Leukemia","volume":"198","author":"Yin","year":"2017","journal-title":"J Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e1242544","DOI":"10.1080\/2162402X.2016.1242544","article-title":"Ibrutinib as an Antitumor Immunomodulator in Patients With Refractory Chronic Lymphocytic Leukemia","volume":"5","author":"Cubillos-Zapata","year":"2016","journal-title":"Oncoimmunology"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-593137","article-title":"Ibrutinib Enhances the Antitumor Immune Response Induced by Intratumoral Injection of a TLR9 Ligand in Mouse Lymphoma","volume":"125","author":"Sagiv-Barfi","year":"2015","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s40425-019-0796-5","article-title":"A New Synthetic Toll-Like Receptor 1\/2 Ligand is an Efficient Adjuvant for Peptide Vaccination in a Human Volunteer","volume":"7","author":"Rammensee","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2839","article-title":"ProteomeXchange Provides Globally Coordinated Proteomics Data Submission and Dissemination","volume":"32","author":"Vizcaino","year":"2014","journal-title":"Nat Biotechnol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.705974\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T09:33:07Z","timestamp":1672738387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.705974\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":92,"alternative-id":["10.3389\/fimmu.2021.705974"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.705974","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"article-number":"705974"}}